This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amakem Sponsors Ophthalmology Chair At KU Leuve

DIEPENBEEK, Belgium, April 8, 2013 /PRNewswire/ --

Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has sponsored a new Chair of Ophthalmology Translational Research at the Catholic University Leuven (KU Leuven), Belgium.

The Chair has been established by the University and Amakem to drive further translational research into the prevention of diseases leading to impaired vision or blindness with a special emphasis on glaucoma. It will be held by Professor Ingeborg Stalmans, head of the glaucoma clinic of the Ophthalmology Department at the University Hospital in Leuven (UZLeuven). Professor Stalmans also runs an ophthalmology laboratory at KU Leuven and is a member of Amakem's Clinical Advisory Board.

Professor Stalmans said: "Amakem is a relatively young company to sponsor a Chair at a leading University and it is a measure of the maturity of their approach. As a member of the Amakem Clinical Advisory Board, I have had the opportunity to work closely with them as they have advanced AMA0076 into the clinic as a highly promising new treatment for glaucoma and ocular hypertension. I am grateful for the opportunity presented by the Chair to advance work into the science underlying glaucoma and other diseases and look forward to this work being translated into new medicines."

The KU Leuven Chair sponsorship is intended to further fundamental research and the Chair holder is appointed by the Rector of the University on the recommendation of the Dean of the relevant faculty. The Chair holder can use the gift to fund teaching or research. Amakem has initially committed to funding the Chair for three years.

Dr. Jack Elands, CEO of Amakem, said: "It is with great pride that we make this announcement. We have already established a very strong relationship with KU Leuven  and this sponsorship will serve to build on that and provide valuable funding to research aimed at improving treatment for patients with sight threatening conditions. We look forward to new insight being generated, particularly improved understanding of the causes and potential treatment of glaucoma."

In healthy eyes, aqueous humor flows through the eye and exits, primarily via the trabecular meshwork, to maintain the appropriate intraocular pressure. In glaucoma, increased pressure leads to damage of the optic nerve resulting in vision loss and ultimately blindness. It is expected that Prof. Stalmans will focus part of her work as Chair of Ophthalmology Translational Research on strategies to improve eye health by restoring the function of the trabecular meshwork.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs